Can Johnson & Johnson’s RIPTAC bet deliver the next wave of targeted oral cancer drugs?
Johnson & Johnson’s $3B Halda acquisition brings RIPTACs into focus. Find out what it means for prostate cancer therapy and precision oncology.
Genmab ends acasunlimab trials: What it signals about bispecific immunotherapy risk
Genmab ends development of acasunlimab to focus on EPKINLY, petosemtamab, and Rina-S. Find out what this shift means for 4-1BB bispecifics today.
Why Verastem Oncology’s KRAS G12C trial exit reveals a calculated pivot to next-generation lung cancer targets
Verastem exits its G12C lung cancer trial to prioritize VS-7375, a next-gen G12D inhibitor showing promise. Find out how this pivot could change KRAS therapy.
NeoImmuneTech takes over Endari’s U.S. rights from Emmaus: What this signals for the future of sickle cell treatment
NeoImmuneTech takes over U.S. rights for Endari from Emmaus Life Sciences. Find out what this deal reveals about the future of sickle cell treatment.
Delcath subgroup data links survival to tumor burden and LDH in uveal melanoma
New Phase 3 subgroup data suggest Delcath’s HEPZATO KIT improves survival in patients with lower tumor burden or LDH. Learn what this means for mUM treatment.
Elanco wins USDA approval for Befrena, expanding mAb options in canine dermatitis
USDA approves Elanco’s Befrena for canine allergic dermatitis. Find out what it means for vets, pet owners, and the mAb dermatology race.
AstraZeneca, Daiichi Sankyo push Enhertu into early breast cancer with new FDA nod
AstraZeneca PLC and Daiichi Sankyo’s HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for use in patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant treatment and are at high risk of recurrence. The designation is based on positive results […]
From Parkinson’s to platform scalability: What’s next for Sinopia’s LEADS technology
Sinopia Biosciences receives NIH grant to expand its LEADS platform. Find out how AI and metabolomics could transform drug discovery.
Corcept’s relacorilant CRL leaves endocrinology ambitions in limbo as oncology pivot takes center stage
Find out why FDA’s complete response letter for Corcept’s relacorilant could reshape treatment of hypercortisolism, with implications for oncology approval.
Can a global trials map help fix spondyloarthritis’s fragmented development landscape?
Explore what global spondyloarthritis trial trends in 2025 reveal about innovation gaps, sponsor risk, and regulatory hurdles. Read the full industry analysis.